21:18 , Feb 2, 2017 |  BC Extra  |  Financial News

Versant leads Tarveda’s $30M D round

Tarveda Therapeutics Inc. (Watertown, Mass.) said it raised $30 million in a series D round led by new investor Versant Ventures . Existing investors New Enterprise Associates , Novo A/S , NanoDimension and Flagship Pioneering...
08:00 , Feb 1, 2016 |  BioCentury  |  Finance

Un-Blended

A year after unveiling its Pentarin platform, Tarveda Therapeutics Inc. and its investors have seen enough data to exclusively focus the cancer company on its biologic-drug conjugates. Tarveda (formerly Blend Therapeutics Inc. ) last week...
02:24 , Jan 28, 2016 |  BC Extra  |  Financial News

Tarveda raises $38M series C

Tarveda Therapeutics Inc. (Watertown, Mass.) raised $38 million in a series C round led by new investor Novo A/S (Hellerup, Denmark) and founding investor New Enterprise Associates. Existing investors Flagship Ventures, NanoDimension and Eminent Venture...
02:25 , Apr 14, 2015 |  BC Extra  |  Company News

Management tracks

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) hired Ramona Sequeira as president of its U.S. business unit. She succeeds Doug Cole, who stepped down March 31. Sequeira was VP of Lilly USA at Eli Lilly and Co....
08:00 , Jan 26, 2015 |  BioCentury  |  Emerging Company Profile

Cloaking conjugates

After spending its first 18 months using medicinal chemistry to discover novel platinum-based cytotoxic agents for cancer, Blend Therapeutics Inc. has decided to branch out into developing a biologic-drug conjugate platform that may provide greater...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Financial News

Blend Therapeutics financial update

Blend Therapeutics Inc. , Watertown, Mass.   Business: Combinatorial biology, Cancer, Inflammation   Date announced: 2015-01-07   Note: Blend Therapeutics raised $21 million through an undisclosed combination of series B and venture debt funding in...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Blend(ing) a platform

A fresh capital infusion has provided Blend Therapeutics Inc. the opportunity to develop a platform to optimize the delivery of its cytotoxic agents to cancer cells - a challenge identified by investors as the main...
02:42 , Jan 8, 2015 |  BC Extra  |  Financial News

Cancer play Blend raises $21M

Cancer company Blend Therapeutics Inc. (Watertown, Mass.) raised $21 million through an undisclosed combination of equity and debt. The equity portion -- an extension of a series B round -- came from existing investors Flagship...
02:42 , Jan 8, 2015 |  BC Extra  |  Financial News

Cancer play Blend raises $21M

Cancer company Blend Therapeutics Inc. (Watertown, Mass.) raised $21 million through an undisclosed combination of equity and debt. The equity portion -- an extension of a series B round -- came from existing investors Flagship...
07:00 , Aug 18, 2014 |  BioCentury  |  Finance

Flagship's fashion

Venture investment models come and go out of fashion, but Flagship Ventures has stuck with its thesis that novel, early stage platform companies with significant disruptive potential are the way to go. And rather than...